What We're Reading: Page 90
Industry reads hand-picked by our editors
Jan 30, 2023
Jan 27, 2023
-
Reuters
U.S. Senator Warren ‘particularly concerned’ about Amgen, Indivior deals
-
Financial Times
Big pharma groups rejoin battle with governments on drug prices
-
Evaluate Vantage
US regulator stays firm on knockbacks
-
Fierce Biotech
Early data from AC Immune Alzheimer’s vaccine suggests response
Jan 26, 2023
Jan 25, 2023
Jan 24, 2023
-
Bloomberg
Pharma CEOs Among Likely Targets for Democrats’ Subpoenas
-
Healthcare Dive
Amazon doubles down on generic drugs with new RxPass subscription
-
The Wall Street Journal
Drug Distributor AmerisourceBergen to Change Name to Cencora
-
The Timmerman Report
Biotech Needs to Get Back to Work in Person. Now.
Jan 23, 2023
-
The Boston Globe
‘Holding on by its fingernails.’ The biotech industry in Massachusetts braces for another tough year.
-
CNBC
FTC asks judge to hold ‘pharma bro’ Martin Shkreli in contempt of court for forming new drug firm
-
Financial Times
China’s drug-pricing policy impedes biotech profits
-
Fierce Pharma
Novo hit by 60 Minutes ‘paid’ Wegovy news program allegations
Previous
